浙江醫藥(600216.SH)半年度淨利潤降40.09%至2.81億元
格隆匯8月22日丨浙江醫藥(600216.SH)發佈2019年半年度報告，實現營業收入35.86億元，同比增長5.69%；歸屬於上市公司股東的淨利潤2.81億元，同比下降40.09%；歸屬於上市公司股東的扣除非經常性損益的淨利潤2.22億元，同比下降52.55%；基本每股收益0.296元。
報告期內，國家醫藥政策改革深入推進，臨牀數據核查、藥品註冊分類改革、優先審評審批、藥品上市許可持有人制度、仿製藥一致性評價、帶量採購等政策相繼落地，醫藥行業競爭激烈，機遇與挑戰並存。公司拓展了國內製劑營銷網絡，制定有效的產品策略，保持優勢品種持續穩定增長，也為潛力品種的後續發力奠定基礎。
報告期內，研發和技術創新工作多點布局。左氧氟沙星片已完成工藝驗證，正在進行穩定性試驗；恩格列淨原料藥及片劑完成工藝開發，準備技術轉移。新藥報批進展順利，取得生產批准文號3個，分別為利奈唑胺葡萄糖注射液二個規格的批准文號(國藥準字H20193017、國藥準字H20193018)及乳酸左氧氟沙星片0.25g的批准文號(國藥準字H20194012)。上報仿製藥一致性評價產品3個，分別為注射用替考拉寧、米格列醇片、乳酸左氧氟沙星片0.25g；上報4類仿製藥1個，為左氧氟沙星氯化鈉注射液。上半年，公司申請發明專利12項，授權發明專利10項。截至2019年6月底，公司累計申請發明專利602項，授權發明專利212項，其中授權國際發明專利63項。
報告期內，保健食品獲得5個備案批准文號。獲得“固體飲料生產許可”，類別包括風味固體飲料、植物固體飲料、蛋白固體飲料等，已有9款產品獲得生產批文，全部可以商業化生產；獲得“壓片糖果生產許可”，已有1款產品獲得生產批文，可以商業化生產；獲得“食品經營許可證”，許可內容包括“預包裝食品(不含冷藏冷凍食品)和保健食品銷售”。
報告期內，昌海園區生命營養品廠在建項目均已接近尾聲。維生素A衍生物項目通過試生產備案，開始投料試生產。年產32180噸維生素製品項目：VE粉飼料級1月份取得生產許可證與產品批准文號，4月份通過FAMI-QS認證，目前處於正常生產狀態；D-生物素粉生產線於3月份完成設備安裝；VD3粉(微粒)生產線於5月份完成設備安裝；VA粉(微粒)生產線於6月份完成設備安裝，目前均處於系統調試狀態。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
